Jane Street Group LLC Has $846,000 Stock Position in Embecta Corp. (NASDAQ:EMBC)

Jane Street Group LLC reduced its position in shares of Embecta Corp. (NASDAQ:EMBC) by 76.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,959 shares of the company’s stock after selling 135,528 shares during the period. Jane Street Group LLC owned approximately 0.07% of Embecta worth $846,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in EMBC. William Blair Investment Management LLC acquired a new position in Embecta during the fourth quarter valued at approximately $15,270,000. Raymond James Financial Inc. acquired a new position in Embecta during the fourth quarter valued at approximately $6,598,000. American Century Companies Inc. raised its position in Embecta by 8.0% during the fourth quarter. American Century Companies Inc. now owns 3,261,934 shares of the company’s stock valued at $67,359,000 after purchasing an additional 242,668 shares in the last quarter. Brandywine Global Investment Management LLC acquired a new position in Embecta during the fourth quarter valued at approximately $4,043,000. Finally, JPMorgan Chase & Co. increased its holdings in shares of Embecta by 121.1% during the fourth quarter. JPMorgan Chase & Co. now owns 321,126 shares of the company’s stock worth $6,631,000 after buying an additional 175,857 shares in the last quarter. 93.83% of the stock is currently owned by institutional investors and hedge funds.

Embecta Stock Performance

Shares of NASDAQ:EMBC opened at $10.72 on Friday. The company has a fifty day moving average of $12.13 and a 200-day moving average of $15.57. The company has a market capitalization of $626.51 million, a PE ratio of 10.72, a price-to-earnings-growth ratio of 0.78 and a beta of 1.24. Embecta Corp. has a 52-week low of $10.27 and a 52-week high of $21.48.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings data on Friday, May 9th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.04. Embecta had a net margin of 5.25% and a negative return on equity of 19.22%. The company had revenue of $259.00 million for the quarter, compared to analysts’ expectations of $261.77 million. During the same quarter in the previous year, the firm posted $0.67 earnings per share. Embecta’s revenue for the quarter was down 9.8% on a year-over-year basis. On average, equities analysts forecast that Embecta Corp. will post 2.85 EPS for the current fiscal year.

Embecta Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Wednesday, May 28th will be paid a $0.15 dividend. The ex-dividend date of this dividend is Wednesday, May 28th. This represents a $0.60 annualized dividend and a dividend yield of 5.60%. Embecta’s dividend payout ratio is 66.67%.

Insider Buying and Selling

In other Embecta news, Director David F. Melcher acquired 10,000 shares of Embecta stock in a transaction that occurred on Friday, May 23rd. The shares were bought at an average price of $10.60 per share, with a total value of $106,000.00. Following the completion of the purchase, the director now directly owns 86,681 shares in the company, valued at $918,818.60. This trade represents a 13.04% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. 0.42% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on EMBC. Mizuho lowered their price target on shares of Embecta from $15.00 to $13.00 and set a “neutral” rating for the company in a report on Friday. Wall Street Zen upgraded shares of Embecta from a “hold” rating to a “buy” rating in a report on Thursday.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.